Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 159, Issue -, Pages 232-244Publisher
ELSEVIER
DOI: 10.1016/j.addr.2020.04.009
Keywords
Sphingolipids; Neurodegeneration; Neuroinflammation; Psychiatric diseases; Lipidomics; Biomarkers; Surrogate markers
Categories
Funding
- ZonMw Memorabel program [733050105]
- International Foundation for Alzheimer Research (ISAO) [14545]
- Hersenstichting [DR-2018-00274]
- Interreg Europe EURLIPIDS program [23]
- National Institute of Health/National Institute of Aging [R01 AG049704]
Ask authors/readers for more resources
Lipids play an important role in neurodegeneration, neuroinflammation, and psychiatric disorders and an imbalance in sphingolipid levels is associated with disease. Although early diagnosis and intervention of these disorders would clearly have favorable long-term outcomes, no diagnostic tests currently exist that can accurately identify people at risk. Reliable prognostic biomarkers that are easily accessible would be beneficial to determine therapy and treatment response in clinical trials. Recent advances in lipidomic investigation methods have greatly progressed the knowledge of sphingolipids in neurodegenerative and psychiatric disorders over the past decades although more longitudinal studies are needed to understand its exact role in these disorders to be used as potential tools in the clinic. In this review, we give an overview of the current knowledge of sphingolipids in neurodegenerative and psychiatric disorders and explore recent advances in investigation methods. Finally, the potential of sphingolipid metabolism products and signaling molecules as potential biomarkers for diagnosis, prognostic, or surrogate markers of treatment response is discussed. (C) 2020 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available